

# Adult CIRB - Late Phase Emphasis Meeting Agenda

## May 20, 2021

## I Continuing Review

**10272**, A Phase II Multi-Institutional Trial to Evaluate Prostate Specific Membrane Antigen (PSMA)-Based PET Imaging of High Risk Prostate Cancer (Protocol Version Date 04/02/21)

## II Continuing Review

**A021602**, Randomized, Double-Blinded Phase III Study of Cabozantinib Versus Placebo in Patients with Advanced Neuroendocrine Tumors After Progression on Prior Therapy (CABINET) (Protocol Version Date 07/24/20)

## III Continuing Review

**A021804**, A Prospective, Multi-Institutional Phase II Trial Evaluating Temozolomide vs Temozolomide and Olaparib for Advanced Pheochromocytoma and Paraganglioma (Protocol Version Date 10/23/20)

## **IV** Continuing Review

A051301, A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation versus Placebo in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype (Protocol Version Date 05/22/19)

### V Continuing Review

A051701, Randomized Phase II/III Study of Venetoclax (ABT 199) Plus Chemoimmunotherapy for MYC/BCL2 Double-Hit and Double-Expressing Lymphomas (Protocol Version Date 08/03/20)



# VI Continuing Review

**EA2174**, A Phase II/III Study of Peri-operative Nivolumab and Ipilimumab in Patients with Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma (Protocol Version Date 01/20/21)

## VII Continuing Review

**EAA173**, Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM) (Protocol Version Date 10/22/20)

## VIII Continuing Review

**N0577**, N0577 (CODEL): Phase III Intergroup Study of Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma (Protocol Version Date 10/22/18)

## IX Continuing Review

NRG-BN007, A Randomized Phase II/III Open-Label Study of Ipilimumab and Nivolumab versus Temozolomide in Patients with Newly Diagnosed MGMT (Tumor O-6-Methylguanine DNA Methyltransferase) Unmethylated Glioblastoma (Protocol Version Date 02/09/21)

## **X** Continuing Review

NRG-GU002, Phase II-III Trial of Adjuvant Radiotherapy and Androgen Deprivation following Radical Prostatectomy with or without Adjuvant Docetaxel (Protocol Version Date 08/26/19)

### XI Continuing Review

NRG-GU005, Phase III IGRT and SBRT vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer (Protocol Version Date 01/23/20)

### XII Continuing Review

NRG-GY021, A Phase II Randomized Trial of Olaparib Versus Olaparib Plus Tremelimumab In Platinum-Sensitive Recurrent Ovarian Cancer (Protocol Version Date 04/24/20)



## XIII Continuing Review

**S1216**, A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 with Androgen Deprivation Therapy + Bicalutamide in Patients with Newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer (Protocol Version Date 04/07/17)

## XIV Continuing Review

**S1609**, DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (Protocol Version Date 01/19/21)

## XV Continuing Review

**S1931**, Phase III Trial Of Immunotherapy-Based Combination Therapy With Or Without Cytoreductive Nephrectomy For Metastatic Renal Cell Carcinoma (Probe Trial) (Protocol Version Date 03/03/21)

## XVI New Study - Initial Review

**AMC-111**, Impact of Behavior Modification Interventions and Lung Cancer Screening on Smoking Cessation in People Living with HIV: A Feasibility Study (Protocol Version Date 03/29/21)

### XVII New Study - Initial Review

NRG-GY024, Groningen International Study on Sentinel Nodes in Vulvar Cancer (GROINSS-V) III: A Prospective Phase II Treatment Trial (Protocol Version Date 04/26/21)

### **XVIII Amendment**

**EAA173**, Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM) (Protocol Version Date 04/16/21)

### XIX Amendment

**NRG-BR004**, A Randomized, Double-Blind, Phase III Trial of Taxane/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer (Protocol Version Date 03/30/21)